Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation

Phase 2

Completed

Conditions: Cardiac Allograft Vasculopathy

Interventions: Drug: Pioglitazone
Drug: Placebo

Registration Number: NCT01186250

Lead Sponsor: Stanford University

Brief Summary: The purpose of this study is to determine the benefit of using the FDA-approved insulin-sensitizing agent, Pioglitazone, on human heart transplant recipients. The objectives of this project are to (1) determine if pioglitazone effectively treats insulin resistance in heart transplant recipients, and (2) to determine whether pioglitazone therapy after heart transplantation impacts the development or progression of cardiac allograft vasculopathy (CAV), a form of chronic rejection after heart transplantation.

Detailed Description: CAV, a rapidly progressive obliterative disease involving the graft coronary arteries, is the leading cause of morbidity and mortality beyond the first year after heart transplantation. This common complication occurs in almost half of recipients within 3 years after heart transplantation, and is associated with high rates of graft failure and mortality. Clinical care of heart transplant recipients in the current era is greatly limited by the lack of effective treatment options to prevent or retard the progression of CAV. CAV appears to be strongly associated with the state of insulin resistance, which is present in over half of heart transplant recipients and is characterized by metabolic abnormalities including glucose intolerance, dyslipidemia, endothelial dysfunction, and high levels of circulating inflammatory markers. Insulin resistance can be effectively treated with pioglitazone, a TZD compound which directly affects tissue insulin sensitivity. In this study, we will enroll 32 insulin-resistant heart transplant recipients and will randomize them to pioglitazone or placebo for a one-year period. We will determine the efficacy of pioglitazone for the treatment of insulin resistance and prevention of the development and progression of CAV after heart transplantation. The data generated from this study will provide important preliminary data for future, larger-scale clinical investigations.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 18

Inclusion Criteria

Heart transplant recipients, years 1-4 post-transplant
Age >= 18 years
Fasting TG/HDL ratio>=3.0 or Fasting TG>=150 mg/dL

Exclusion Criteria

Diabetes mellitus
Severe liver dysfunction (ALT>=2.5 x upper limit of normal)
Severe renal dysfunction (GFR<30 or Stage IV CKD)
Moderate-severe fluid retention
Clinical or echocardiographic signs of left ventricular dysfunction
Contraindication to coronary angiography and/or IVUS

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Pioglitazone	Pioglitazone	Pioglitazone
Placebo	Placebo	Placebo

Primary Outcome Measures

Name	Time	Method
Insulin Levels Area Under Curve(AUC)	Baseline and 1 year	Change from baseline in Insulin Levels During Oral Glucose Tolerance test at 1 year.

Secondary Outcome Measures

Name	Time	Method
Change in Intimal Volume	baseline and 1 year	Intimal volume is defined as external elastic membrane volume minus lumen (luminal) volume measured at the heart Catheterization and intravascular Ultrasound( IVUS)
Change From Baseline in High-sensitivity C-reactive Protein (HsCRP) at One Year	Baseline and 1 year	measure of low levels of C-reactive protein to identify low but persistent levels of inflammation
Change in Maximal Intimal Thickness(MIT) by Intravascular Unltrasound(IVUS)	Baseline and 1 year	The change in maximal intimal thickness (MIT) from baseline to one year was recorded for several matched sites in the same coronary artery, the cross sections, predominantly in the left anterior descending coronary artery, from baseline to one-year follow-up, were studied. The IVUS cross sections were matched by using identifiable landmarks in the images, such as bifurcations or arterial calcification, or external landmarks, such as coronary veins or pericardium. In addition, the one-year IVUS studies were obtained with an angiographic roadmap of where the initial IVUS study was performed along the length of the vessel. The IVUS system auto pullback was performed at .5 mm/s from the mid-distal portion of the study vessel, where an easily identifiable landmark was visible (i.e., branchpoint). The following items were measured for each patient: maximal intimal thickness (MIT), intimal area (IA), and vessel area.
Change From Baseline in ADMA (Asymmetric Dimethylarginine) at One Year.	Baseline and 1 year	Competitive ELISA assay in Stanford laboratory.
Change From Baseline in TG/HDL Ratio at One Year	Baseline and 1 year	Triglyceride ratio to High Density Lipoprotien
Change in Levels of Fasting Glucose at Baseline and 1 Year	Baseline and 1 year	Oral Glucose Tolerance Test : blood was drawn for fasting plasma glucose and insulin levels, followed by ingestion of a solution containing 75grams of glucose. Repeat blood samples were collected for glucose and insulin levels at 30, 90, and 120 minutes after glucose ingestion. All glucose measurements were performed by the Clinical Translational Research Unit (CTRU) Stanford University.